Submit Your Article CMED MEACR meeting
An official publication of the Middle-Eastern Association for Cancer Research
Clinical Cancer Investigation Journal
JCR Impact Factor: 0.1
Year: 2018   |   Volume: 7   |   Issue: 2   |   Page: 56-61     View issue

Orofacial Rhabdomyosarcoma: A 5-year Clinicopathologic Study from Sub-Saharan Africa

Adebayo Ibikunle, Abdurrazaq Taiwo, Ramat Braimah, Kabir Abdullahi, Usman Malami

Background: Rhabdomyosarcoma (RMS) is an aggressive malignant neoplasm of mesenchymal origin. Its common sites of occurrence are the extremities and the genitourinary system, being less frequently seen in the orofacial region. There is paucity of literature, especially from sub-Saharan Africa on orofacial RMS. Materials and Methods: Records of all patients managed for orofacial RMS between January 2013 and November 2017 at the Department of Dental and Maxillofacial surgery of Usmanu Danfodiyo University Teaching Hospital were obtained. Data retrieved include sociodemographics, clinical features (including the tumor, node, and metastasis [TNM] stage and Intergroup RMS Study risk classification), histological type, and mode of treatment. Data were recorded and analyzed using IBM SPSS Statistics for Windows version 20 (Armonk, IBM Corp., NY, USA). Results: Twenty-one patients were included. There were 17 (81.0%) males and 4 (19.1%) females, giving a male-to-female ratio of 4.3:1. Age ranged from 2 to 76 years (mean [±standard deviation] of 15.8 [±16.8]). Majority of them belonged to the low socioeconomic group. The duration of the symptoms ranged from 2 to 9 months. The midface was the most commonly involved sites. Majority of the cases were nonparameningeal 14 (66.7%). Regional nodal metastasis was clinically present in 9 (42.9%) cases. Embryonal RMS was the most frequently encountered histological type (11 [52.4%]). Treatment was multimodal in 11 (52.4%) cases and 3 (14.1%) had recurrence. Conclusion: Orofacial RMS may occur in any age group although it may be more commonly seen in the first decade of life. Unimodal treatment may be successfully deployed in carefully selected cases. Prognosis remains poor in our climes.

Cite this article
Ibikunle A, Taiwo A, Braimah R, Abdullahi K, Malami U. Orofacial Rhabdomyosarcoma: A 5-year Clinicopathologic Study from Sub-Saharan Africa. Clin Cancer Investig J. 2018;7(2):56-61.
Ibikunle, A., Taiwo, A., Braimah, R., Abdullahi, K., & Malami, U. (2018). Orofacial Rhabdomyosarcoma: A 5-year Clinicopathologic Study from Sub-Saharan Africa. Clinical Cancer Investigation Journal, 7(2), 56-61.

Sitemap | What's New | Feedback | Copyright and Disclaimer | Privacy Notice
© Clinical Cancer Investigation Journal | Published by Polaris Publication
Online since 01 December, 2011
Editorial and Ethics Policies
Creative Commons  Open Access Journal View mobile site 
ISSN: Print -2278-1668, Online - 2278-0513